Supernus Pharma (SUPN) Misses Q1 EPS by 58c, Beats on Revenue

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of ($0.21), $0.58 worse than the analyst estimate of $0.37. Revenue for the quarter came in at $149.8 million versus the consensus estimate of $146.9 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Gyre Therapeutics (GYRE) files for 31.03M share offering by selling stockholders
• Cadrenal Therapeutics (CVKD) files for 2.94M share offering by sellign stockholders